… to consider whether and how to use these new vaccines. This … on HPV and HPV vaccines
for policy-makers. It is based on a longer document (“Human Papillomavirus and HPV vaccines…

… it was assumed that there was only one human papillomavirus (HPV) and that it was the
cause of various warty lesions that decorated different tissue sites. HPV was seen, except in rare …

… Currently available prophylactic HPV vaccines are based on virus-like particles that self-…
The first HPV vaccine was licensed in 2006. All vaccines target HPV-16 and HPV-18, types …

… data on HPV vaccination status, HPV DNA status, and other HPV-associated … HPV vaccine
impact after three years for quadrivalent vaccine [18] and after four years for bivalent vaccine …

… current evidence regarding the safety of HPV vaccines. In summary, both … vaccine uptake
[19, 20]. This review aimed to assess all available published safety data on both HPV vaccines, …

… Introduction: Identification of human papillomavirus (HPV) as … and therapeutic HPV vaccines
to control HPV-associated … As research in the development of HPV vaccines continues, …

… ) and a bivalent (bHPVv) vaccine. Since 2008, HPV vaccination programmes have been …
and recent evidence on safety of HPV vaccines, including both severe and non-severe AEs. …

… HPV vaccines—the bivalent vaccine comprising HPV types 16 and 18, and the quadrivalent
vaccine comprising HPV … the methods used to verify the effectiveness of HPV vaccination. …

… Safety (GACVS) of WHO recently published a safety update on HPV vaccines and commented:
In summary, 4 years after the last review of HPV vaccine safety and with more than 170 …

… Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human
papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006;367:…